Pharmacology and Therapeutics

Early Treatment with Fluvoxamine Among Patients with COVID-19: A Cost-Consequence Model
Fergal P. Mills, Gilmar Reis, Kristian Thorlund, Jamie I. Forrest, Christina M. Guo, David R Boulware, Edward J. Mills, for the TOGETHER Investigators

medRxiv 2021.12.23.21268352; doi: https://doi.org/10.1101/2021.12.23.21268352

Add to Selected Citations
A Quantitative Systems Pharmacology Model of the Pathophysiology and Treatment of COVID-19 Predicts Optimal Timing of Pharmacological Interventions
Rohit Rao, Cynthia J. Musante, Richard Allen

medRxiv 2021.12.07.21267277; doi: https://doi.org/10.1101/2021.12.07.21267277

Add to Selected Citations
Probing Gut-Brain Links in Alzheimer’s Disease with Rifaximin
Paul V. Suhocki, James S. Ronald, Anna Mae E. Diehl, David M. Murdoch, P. Murali Doraiswamy

medRxiv 2021.11.22.21266123; doi: https://doi.org/10.1101/2021.11.22.21266123

Add to Selected Citations
Electroconvulsive therapy effects on anhedonia and reward circuitry anatomy: a dimensional structural neuroimaging approach
Marta Cano, Erik Lee, Alexis Worthley, Kristen Ellard, Tracy Barbour, Carles Soriano-Mas, Joan A. Camprodon

medRxiv 2021.11.16.21266190; doi: https://doi.org/10.1101/2021.11.16.21266190

Add to Selected Citations
PBPK modelling of dexamethasone in patients with COVID-19 and liver disease
Maiara Camotti Montanha, Nicolas Cottura, Michael Booth, Daryl Hodge, Fazila Bunglawala, Hannah Kinvig, Sandra Grañana-Castillo, Andrew Lloyd, Saye Khoo, Marco Siccardi

medRxiv 2021.11.10.21266141; doi: https://doi.org/10.1101/2021.11.10.21266141

Add to Selected Citations
Population Pharmacokinetic Analysis of Dexmedetomidine in Children using Real World Data from Electronic Health Records and Remnant Specimens
Nathan T. James, Joseph H. Breeyear, Richard Caprioli, Todd Edwards, Brian Hachey, Prince J. Kannankeril, Jacob M. Keaton, Matthew D. Marshall, Sara L. Van Driest, Leena Choi

medRxiv 2021.05.03.21256553; doi: https://doi.org/10.1101/2021.05.03.21256553

Add to Selected Citations
Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming
R.S.G. Sablerolles, W.J.R. Rietdijk, A. Goorhuis, D.F. Postma, L.G. Visser, D. Geers, K.S. Schmitz, H.M. Garcia Garrido, M.P.G. Koopmans, V.A.S.H. Dalm, N.A. Kootstra, A.L.W. Huckriede, M. Lafeber, D. van Baarle, C.H. GeurtsvanKessel, R.D. de Vries, P.H.M. van der Kuy

medRxiv 2021.10.18.21264979; doi: https://doi.org/10.1101/2021.10.18.21264979

Add to Selected Citations
Reducing the use of sleep-inducing drugs during hospitalization by a multi-faceted intervention – a pilot study
Stephanie Heinemann, Jonas Klemperer, Eva Hummers, Roland Nau, Wolfgang Himmel

medRxiv 2021.10.06.21264630; doi: https://doi.org/10.1101/2021.10.06.21264630

Add to Selected Citations
Frailty and rate of fractures in patients initiating antihypertensive medications: a cohort study in primary care
Marc F Österdahl, Sarah-Jo Sinnott, Ian Douglas, Andrew Clegg, Laurie Tomlinson, Angel Wong

medRxiv 2021.10.02.21264455; doi: https://doi.org/10.1101/2021.10.02.21264455

Add to Selected Citations
Deleterious drugs in COVID-19: a rapid systematic review and meta-analysis
Michael Holder, Catherine Heeney, Stephen Malden, Uditha Perera, Aziz Sheikh

medRxiv 2021.09.17.21262724; doi: https://doi.org/10.1101/2021.09.17.21262724

Add to Selected Citations

Pharmacology and Therapeutics

Pages